Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

About this update from Hercules Capital, Inc.

[{"type":"text","content":"April 10, 2026 Target Action Date for RP1 in Advanced Melanoma","length":62,"tagName":"p"},{"type":"text","content":"WOBURN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal third quarter ended December 31, 2025 and provided a business update.","length":307,"tagName":"p"},{"type":"text","content":"The Company's Biologics License Application (BLA) resubmission for RP1 (vusolimogene oderparepvec) in anti-PD-1 failed melanoma was accepted by the FDA in October 2025 with a Prescription Drug User Fee Act (PDUFA) target action date of April 10, 2026. Commercial readiness activities are well underway to support a potential launch, if approved.","length":349,"tagName":"p"},{"type":"text","content":"The Company has amended its existing loan agreement with Hercules Capital, Inc. The amendment included the draw down of $35 million upon closing and the potential to draw another $120 million at post approval milestones. The amendment also delays the repayment of debt from 2026 to 2027. The Company has extended its cash runway late into to the first quarter of 2027.","length":368,"tagName":"p"},{"type":"text","content":""We have been engaged with the FDA in the review of the BLA resubmission for RP1,” said Sushil Patel, Ph.D., CEO of Replimune. "Advanced melanoma patients can progress quickly and are in urgent need of safe and effective treatment options. Our team remains ready to launch RP1 with commercial supply produced and the commercial organization prepared to engage with our target accounts rapidly, assuming FDA approval.”","length":427,"tagName":"p"},{"type":"text","content":"Program Highlights & Milestones","length":35,"tagName":"p"},{"type":"text","content":"RP1 (vusolimogene oderparepvec)","length":31,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"IGNYTE-3 Confirmatory Study: The global Phase 3 trial will enroll approximately 400 patients and is assessing RP1 in combination with nivolumab versus physician's choice in patients with advanced melanoma who have progressed on anti-PD-1 and anti-CTLA-4 therapies or are ineligible for anti-CTLA-4 treatment. The primary endpoint of this trial is overall survival, a...

More updates from Hercules Capital, Inc.